Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

Phase 2

Terminated

• Conditions: Pyoderma Gangrenosum
• Interventions: Drug: APD334

• Registration Number: NCT03072953
• Lead Sponsor: Arena Pharmaceuticals

Brief Summary

The purpose of this Phase 2a, open label, proof-of-concept clinical study is to assess the efficacy and safety of etrasimod (APD334) in patients with Pyoderma Gangrenosum.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-02-17
• Study First Submitted QC: 2017-03-02
• Study First Posted: 2017-03-08
• Study Start: 2017-06-07
• Primary Completion: 2018-05-22
• Study Completion: 2018-05-22
• Disposition First Submitted: 2019-05-20
• Disposition First Submitted QC: 2019-05-20
• Disposition First Posted: 2019-05-24
• Status Verified: 2021-05
• Results First Submitted: 2021-05-12
• Results First Submitted QC: 2021-05-14
• Last Update Submitted: 2021-05-14
• Results First Posted: 2021-06-11
• Last Update Posted: 2021-06-11

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

1. Male or female (18-80 years).

2. Able to provide a signed informed consent prior to any study related procedure being conducted.

3. Diagnosis of PG with active, non-healing ulcer.

4. Considered to be in stable health in the opinion of the investigator as determined by:

   1. A screening physical examination with no clinically significant abnormalities unrelated to PG.
   2. Vital signs at screening: pulse rate ≥ 55 bpm, systolic blood pressure ≥ 90 mmHg, and diastolic blood pressure ≥ 55 mmHg.
   3. Liver function tests (alanine aminotransferase/aspartate aminotransferase, bilirubin and alkaline phosphatase) < 2x the upper limit of normal.
   4. All other pre-study clinical laboratory findings within normal range, or if outside of the normal range are not deemed clinically significant in the opinion of the investigator with exemption to leucopenia and lymphopenia - please refer to exclusion criterion 24.
   5. No clinical abnormalities noted in the12-lead electrocardiogram in the opinion of the investigator (Refer also to exclusion criterion 13).
   6. No evidence of macular edema in an ophthalmology evaluation (performed by an ophthalmologist), supported with optical coherence tomography, where available (dependent on site capability) at screening.

5. Eligible male and female participants must agree not to participate in a conception process (i.e. active attempt to let female partner to become pregnant or to impregnate, sperm donation, oocyte donation, in vitro fertilization) for at least 30 days after the last dose of study drug.

Non-sterile participants who are sexually active must take adequate contraception measures.

Exclusion Criteria

1. Clinically significant infection as judged by the investigator with an end date less than 6-weeks prior to treatment start (Day 1). In case of infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection, this infection must have ended at least 8 weeks prior to Day 1.
2. Infection with hepatitis C virus anytime in the past; confirmed active infection with hepatitis B virus at screening.
3. History of severe renal or severe hepatic impairment.
4. Current active or latent tuberculosis (TB).
5. A positive diagnostic TB test at screening.
6. Exposure to B-cell or T-cell targeted therapies (such as natalizumab, rituximab, abatacept) within 5 half-lives prior to Day 1.
7. Exposure to other immunosuppressive, immunomodulating or antineoplastic agents.
8. Receipt of any investigational agent within 30 days or 5 half lives (whichever is longer), prior to Day 1.
9. Use of moderate to strong inhibitors of CYP2C9.
10. Abnormal forced expiratory volume (FEV1) or forced vital capacity (FVC).
11. Any known history of congenital or acquired immuno-deficiency.
12. Recent history (within 6 months of screening visit) of cardio- or cerebrovascular disease, acute coronary syndrome, myocardial infarction, unstable angina, cerebro-vascular accident, including transient ischemic attack.
13. History or presence of cardiac arrhythmia, conduction system disease, or use of Class Ia or Class III anti arrhythmic agents, or baseline QTc ≥ 500 msec.
14. Congestive heart failure (NYHA III or NYHA IV)
15. Any surgical procedure requiring general anesthesia within 30 days prior to Day 1 or plans to undergo major surgery during the study period.
16. History of retinal macular edema.
17. History of or signs and symptoms of progressive multifocal leukoencephalopathy (PML) as assessed by the PML checklist at screening.
18. History of more than one episode of herpes zoster or any episode of disseminated zoster.
19. Participants without documented positive varicella zoster virus (VZV) IgG antibody status or participants who have not completed VZV vaccination within 6 weeks prior to Day 1.
20. Receipt of live vaccine within 6 weeks prior to Day 1.
21. History of lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorder, or multiple myeloma.
22. History of malignancy except for adequately treated basal cell skin cancer and in situ carcinoma of the cervix of the uterus that have been completely excised with documented, clear margins.
23. History of severe allergic or anaphylactic reactions requiring medical attention.
24. Leukopenia or lymphopenia at screening.
25. Current or recent history (within 1 year prior to Day 1) of alcohol dependence or illicit drug use.
26. Active psychiatric problems that, in the investigator's opinion, may interfere with compliance with the study procedures.
27. History of any other clinically significant medical condition that, in the investigator's opinion, would preclude participant from safe participation in the study.
28. Inability to attend all the study visits or comply with study procedures.
29. Prior exposure to etrasimod (APD334) or prior participation in any study of etrasimod (APD334).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
APD334	APD334	APD334 active treatment for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Exploratory Endpoint - Change From Baseline in Dermatology Life Quality Index (DLQI) Score	Week 12	The DLQI questionnaire assessed how much a participant's life is affected through their skin problem in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure and sport activities, work or school activities, personal relationships and treatment- related feelings. Participants responded to the 10 questions on a scale from 0 (not at all) to 3 (very much) with a total score ranging from 0 to 30. Higher scores indicated that the skin problem had an extremely large effect on the participant's life whereas lower scores indicated that the disease has minimal to no effect at all.
Exploratory Endpoint - Change From Baseline in C-reactive Protein Levels	Week 12
Exploratory Endpoint - Assessments of Target Lesions	Week 12	Changes in surface area
Exploratory Endpoint - Assessment of Punch Biopsies	Week 12	Changes in histology.
Exploratory Endpoint - Change From Baseline in Physician Global Assessments for Active Skin Manifestations	Week 12	The physician's global assessment for active skin manifestations recorded the number of ulcers, target lesion noted for endpoint evaluation, diameters of each target lesion and score of evaluation at each visit. The scores ranged from 0 (total resolution) to 4 (no evidence of healing).
Exploratory Endpoint - Change From Baseline in Patient Global Assessments for Active Skin Manifestations	Week 12	The patient global assessment for active skin manifestation recorded the disease and pain severity using a visual analogue to mark the participant's score. Participants were asked to rate their disease severity from "not severe" to "extremely severe" and pain levels from "no pain at all' to "worst pain imaginable" in the past one week.

Trial Locations

Locations (6)

Veracity Clinical Research; 🇦🇺 Woolloongabba, Queensland, Australia

Fremantle Dermatology; 🇦🇺 Fremantle, Western Australia, Australia

Royal Melbourne Hospital; 🇦🇺 Parkville, Victoria, Australia

Braemar Day Hospital; 🇳🇿 Hamilton, New Zealand

Eastern Clinical Research Unit; 🇦🇺 Box Hill, Victoria, Australia

Westmead Hospital; 🇦🇺 Westmead, New South Wales, Australia